275 related articles for article (PubMed ID: 30238408)
1. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.
Zahid KR; Han S; Zhou F; Raza U
Cell Oncol (Dordr); 2019 Feb; 42(1):55-66. PubMed ID: 30238408
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
3. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.
Zhao JJ; Pan K; Li JJ; Chen YB; Chen JG; Lv L; Wang DD; Pan QZ; Chen MS; Xia JC
PLoS One; 2011; 6(10):e26608. PubMed ID: 22028922
[TBL] [Abstract][Full Text] [Related]
4. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
[TBL] [Abstract][Full Text] [Related]
5. Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Hu B; Yan X; Liu F; Zhu C; Zhou H; Chen Y; Liu J; Gu X; Ni R; Zhang T
Pathol Oncol Res; 2016 Jul; 22(3):555-65. PubMed ID: 26715439
[TBL] [Abstract][Full Text] [Related]
6. Potential dual functional roles of the Y-linked RBMY in hepatocarcinogenesis.
Kido T; Tabatabai ZL; Chen X; Lau YC
Cancer Sci; 2020 Aug; 111(8):2987-2999. PubMed ID: 32473614
[TBL] [Abstract][Full Text] [Related]
7. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
9. A liver-specific lncRNA, FAM99B, suppresses hepatocellular carcinoma progression through inhibition of cell proliferation, migration, and invasion.
Mo M; Liu S; Ma X; Tan C; Wei L; Sheng Y; Song Y; Zeng X; Huang D; Qiu X
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2027-2038. PubMed ID: 31243545
[TBL] [Abstract][Full Text] [Related]
10. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
11. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
12. Long Noncoding RNA
Gong X; Zhu Z
Cancer Biother Radiopharm; 2020 Jun; 35(5):387-396. PubMed ID: 32315535
[No Abstract] [Full Text] [Related]
13. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5.
Gao W; Lu YX; Wang F; Sun J; Bian JX; Wu HY
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7874-7883. PubMed ID: 31599412
[TBL] [Abstract][Full Text] [Related]
14. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.
Chen L; Guan H; Gu C; Cao Y; Shao J; Wang F
Tumour Biol; 2016 Feb; 37(2):2497-507. PubMed ID: 26385772
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
16. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
17. LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axis.
Hu WY; Wei HY; Li KM; Wang RB; Xu XQ; Feng R
Biomed Pharmacother; 2020 Jan; 121():109642. PubMed ID: 31731191
[TBL] [Abstract][Full Text] [Related]
18. Follistatin-like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase-dependent apoptosis and regulating Bcl-2 family proteins.
Li C; Dai L; Zhang J; Zhang Y; Lin Y; Cheng L; Tian H; Zhang X; Wang Q; Yang Q; Wang Y; Shi G; Cheng F; Su X; Yang Y; Zhang S; Yu D; Wei Y; Deng H
J Cell Mol Med; 2018 Dec; 22(12):6190-6201. PubMed ID: 30255547
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
20. LncRNA HOTAIRM1 inhibits the progression of hepatocellular carcinoma by inhibiting the Wnt signaling pathway.
Zhang Y; Mi L; Xuan Y; Gao C; Wang YH; Ming HX; Liu J
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4861-4868. PubMed ID: 30070317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
